Aller au contenu
Université Echahid Hamma Lakhdar d’El OuedPortail de la recherche
Article

Potential novel HIV-1 reverse transcriptase inhibitors: a modeling and evaluation approach

Malika Mellaoui, Radhia Mazri, Mohamed Mouadh Messaoui, Aicha Kerassa, Mebarka Ouassaf

Résumé

Human immunodeficiency viru (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS), a disease that severely weakens the immune system and makes patients more susceptible to infections. Although there is no definitive cure for HIV, advances in drug development offer promising prospects. In this study, we targeted HIV-1 reverse transcriptase by performing virtual screening (VS) to identify novel candidate compounds. From a database of compounds similar to the inhibitor thymidine-5'-triphosphate (TTP), three compounds (CID441663, CID123650073, and CID123789980) were selected for their docking scores, which outperformed those of the reference compound TTP (-6.2302 kcal/mol). These compounds were then subjected to ADMET, PASS, and DFT analyses. Interestingly, all three ligands showed a broad spectrum of predicted antiviral activity, including targets related to human herpes virus and HIV. Specifically, while TTP primarily targets HIV-1 reverse transcriptase, the top three ligands were predicted to target HIV-1 integrase, with CID441663 and CID123789980 displaying higher confidence in this target compared to CID123650073. These findings suggest that the candidate ligands should undergo further in vitro validation to determine their precise roles as inhibitors or antagonists, and to confirm their selective targeting of HIV-related proteins.

Détails

Langue originaleEnglish
RevueSTUDIES IN HEALTH SCIENCES
Volume5
Numéro4
Pagese9873
ISSN2764-0884
DOI10.54022/shsv5n4-009
Statut de publicationPublié — 29 octobre 2024

Mots-clés

Objectifs de développement durable

  • 3 — Bonne santé et bien-être

Empreinte